Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects
Status:
Completed
Trial end date:
2021-04-19
Target enrollment:
Participant gender:
Summary
It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to
evaluate the pharmacokinetics, safety and immunogenicity of BAT2206 Injection vs Stelara®
(EU-licensed and US-licensed) in healthy Chinese male subjects. A total of 270 healthy male
subjects are planned to be included and randomized at a ratio of 1:1:1 to receive single
45mg/0.5ml BAT2206 Injection or Stelara® (EU-licensed and US-licensed).